Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
You may also be interested in...
US Healthcare Bill's Failure Could Have Unpleasant Ripple Effects For Pharma
Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.
Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity
Inspirion’s MorphaBond win suggests agency’s thinking on three-year exclusivity for abuse-deterrent formulations has ‘evolved’ from a formulation-specific approach to one based on route of abuse.